🔗 Share this article

The first new treatments for gonorrhoea in decades are being viewed as a "major milestone" in the battle against superbug strains of the bacteria, according to researchers.

A Global Challenge

The sexually transmitted infection are escalating worldwide, with estimates suggesting in excess of 82 million instances per year. Notably increased rates are reported in the African continent and nations within the World Health Organization's designated area, which spans from China and Mongolia to New Zealand. In England, cases have hit a historical peak, while infection numbers across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The clearance of fresh medications for gonorrhoea is an significant and necessary step in the face of rising global incidence, escalating drug resistance and the extremely scarce therapeutic options presently on offer.”

Public health authorities are deeply concerned about the increase in antibiotic-resistant strains. The WHO has classified it as a "priority pathogen". A tracking program showed that the effectiveness of key first-line drugs like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Two New Treatment Options Secure Clearance

Zoliflodacin, marketed under the name Nuzolvence, was cleared by the American regulatory agency in recent days for combating gonorrhoea. This disease can lead to major issues, including the inability to conceive. Experts hope that targeted use of this new drug will help delay the emergence of superbugs.

Gepotidacin, created by the pharmaceutical company GlaxoSmithKline, also received approval in close succession. This treatment, which is additionally indicated for urinary tract infections, was shown in trials to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Novel Approach to Creation

This new treatment was the result of a unique collaborative effort for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership collaborated with the drug firm its industry partner to develop it.

“This authorization marks a huge turning point in the management of highly resistant gonorrhoea, which up to this point has been outpacing our drug pipeline.”

Research Study Data and Worldwide Availability

According to results detailed in a prominent scientific publication, zoliflodacin successfully treated over nine in ten of uncomplicated infections. This establishes an similar efficacy with the current standard treatment, which combines a dual-drug approach. The trial involved hundreds of volunteers from several countries including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its unique model, the non-profit has the ability to license and sell the drug in a wide range of regions with limited resources.

Doctors directly involved have voiced positive views. The availability of a easy-to-administer therapy such as this is seen as a "critical tool" for public health efforts. This is considered crucial to alleviate the strain of the infection for people and to halt the transmission of highly drug-resistant gonorrhoea globally.